Moffitt research finds non-small cell lung cancer drug lorlatinib targets additional protein
Lorlatinib co-targets PYK2 and forms a multiprotein complex with SRC suggesting combo therapy could be more beneficial for patients
2023-10-16
(Press-News.org) TAMPA, Fla. — Targeted cancer drugs are widely used because of their ability to inhibit specific proteins involved in cancer development with fewer side effects compared to chemotherapy drugs. But targeted therapies can often inhibit other unknown proteins. These hidden targets may also contribute to the drug’s anticancer effects and potentially offer a path for the drug to be repurposed for other cancers controlled by the hidden target.
In a new study published in Cell Chemical Biology, Moffitt Cancer Center researchers demonstrate this, showing that the ROS1 inhibitor lorlatinib has activity against an additional protein called PYK2. The team also reveals the mechanisms of this inhibition.
“Drugs with polypharmacology mechanisms, meaning agents that target multiple functionally relevant proteins, may have the potential to effectively overcome drug resistance, improve anti-cancer activity of single-targeted inhibitors and produce a more durable patient response and remission,” said Uwe Rix, Ph.D., lead study author and senior member of the Department of Drug Discovery at Moffitt.
Rix and a team of Moffitt researchers wanted to determine whether cancer drugs that target the protein ROS1 in non-small cell lung cancer have additional hidden targets. They performed their studies in cancer models that were driven by the cancer promoting properties of the oncogenic ROS1 protein; therefore, they needed to develop an investigative platform that would be able to identify any potential additional targets that might be hidden by the dominant properties of ROS1.
They first compared the activity of a panel of different ROS1 inhibitors and discovered that the drug lorlatinib had the highest inhibitory activity against ROS1 but also disproportionately high cell viability when compared to other ROS1 inhibitors. These observations suggested that lorlatinib may target additional proteins that contribute to its anticancer effects.
The team performed additional laboratory experiments and found that lorlatinib also targets the protein PYK2. This protein plays an important role in focal adhesions, which are cell structures that are involved in several processes including cell adhesion, movement and survival. Their studies also showed that the protein SRC physically associated with PYK2 and ROS1 and helped control the activity of PYK2. These data suggested that inhibition of ROS1, PYK2 and SRC in combination would have greater anticancer effects than either agent alone.
Further studies confirmed that drug combinations targeting each protein resulted in enhanced cancer cell death and reduced cell survival than either agent alone. Likewise, lorlatinib combined with an SRC inhibitor also resulted in enhanced anticancer effects.
The researchers hope these results and their investigative platform will lead to a better understanding of the mechanisms of action of lorlatinib and the development of drug combinations with improved clinical activity.
This study was supported by the National Cancer Institute (R01 CA181746, P30-CA076292), Department of Defense Lung Cancer Research Program (W81XWH-22-1-0607), Moffitt Lung Cancer Center of Excellence and Moffitt Cancer Center Foundation.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 56 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 9,000 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
###
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-10-16
FOR IMMEDIATE RELEASE
Monday October 16, 2023
Contact:
Jillian McKoy, jpmckoy@bu.edu
Michael Saunders, msaunder@bu.edu
##
Life expectancy has increased substantially for people in the United States with Down syndrome, from a median age of 4 years old in the 1950s to 57 years old in 2019. This longer life span increases the need for adequate healthcare into adulthood for this population, the majority of whom are at high ...
2023-10-16
SAN FRANCISCO — The American Society of Anesthesiologists (ASA) today presented Santhanam Suresh, M.D., MBA, FASA, with its 2023 Excellence in Education Award in recognition of his extraordinary educational contributions to advancing regional anesthesia and pain management in children. The award is presented annually to an ASA member who has made significant contributions to the specialty through excellence in teaching, development of new teaching methods or the implementation of innovative educational programs.
Dr. Suresh is the Arthur C. King professor and chair emeritus of pediatric anesthesiology ...
2023-10-16
SAN FRANCISCO — The American Society of Anesthesiologists (ASA) today honored Karsten Bartels, M.D., Ph.D., MBA., with its 2023 James E. Cottrell Presidential Scholar Award in recognition of his exemplary research to improve patient outcomes in perioperative and critical care medicine and pain management. The award is presented annually to an ASA member who has dedicated their formative career to research.
Dr. Bartels is the Robert Lieberman Endowed Chair in Anesthesiology, vice chair of research and professor of anesthesiology with tenure at the University of Nebraska Medical Center (UNMC) in Omaha. Additionally, he is the inaugural director of the Robert ...
2023-10-16
Amber B. Sansbury, a doctoral candidate in Mason's School of Education, received $24,576 from the U.S. Department of Health and Human Services for the project: "Racial Identity Development of Young Black Children in Early Childhood Education: The Roles of Teachers and Families."
Colleen Vesely, Associate Professor, College of Education and Human Development (CEHD), is serving as Sansbury's adviser.
In this qualitative dissertation study, Sansbury will explore how family engagement vis-a-vis relationships between African American teachers and African American families supports racial socialization and young children's emergent racial ...
2023-10-16
Today, the U.S. Department of Energy (DOE) announced the selection of the High Performance Data Facility (HPDF) hub, which will create a new scientific user facility specializing in advanced infrastructure for data-intensive science. The Thomas Jefferson National Accelerator Facility (JLab) will be the HPDF Hub Director and the lead infrastructure will be located at JLab. The project to build the Hub will be a partnership between JLab and Lawrence Berkeley National Laboratory (LBNL), and the two labs ...
2023-10-16
Beta-diversity serves as a crucial metric for gauging shifts in species composition over spatial or temporal scales, bridging the spectrum between localized (alpha) and broader regional (gamma) diversity. In the fields of ecology, biogeography and conservation biology, to elucidate the origins and sustenance of geographic beta-diversity patterns, we need to explore both the taxonomic and phylogenetic beta-diversity at different evolutionary depths.
In an article published in the KeAi journal Plant Diversity, using a ...
2023-10-16
Neurons, the main cells that make up our brain and spinal cord, are among the slowest cells to regenerate after an injury, and many neurons fail to regenerate entirely. While scientists have made progress in understanding neuronal regeneration, it remains unknown why some neurons regenerate and others do not.
Using single-cell RNA sequencing, a method that determines which genes are activated in individual cells, researchers from University of California San Diego School of Medicine have identified a new biomarker that can be used to predict whether ...
2023-10-16
Imagine the life of a yeast cell, floating around the kitchen in a spore that eventually lands on a bowl of grapes. Life is good: food for days, at least until someone notices the rotting fruit and throws them out. But then the sun shines through a window, the section of the counter where the bowl is sitting heats up, and suddenly life gets uncomfortable for the humble yeast. When temperatures get too high, the cells shut down their normal processes to ride out the stressful conditions and live to feast on grapes on another, cooler day.
This “heat ...
2023-10-16
About The Study: The results of this study including 121,000 Singaporean children ages 1 through 4 suggest that completion of a primary mRNA vaccine series provided protection against SARS-CoV-2 infection. Although incidence of hospitalization and severe illness is low in this age group, there is potential benefit of vaccination in preventing infection and potential sequelae.
Authors: Liang En Wee, M.R.C.P., M.P.H., of the National Centre for Infectious Diseases in Singapore, is the corresponding author.
To access the ...
2023-10-16
About The Study: The findings of this study demonstrated that the incremental changes associated with dementia in regard to older adults’ long-term care and financial burden are substantial. Family care availability should be accounted for in a comprehensive assessment of predicting the effects of dementia.
Authors: Hwa Jung Choi, Ph.D., of the University of Michigan in Ann Arbor, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2023.5482)
Editor’s Note: Please see the article for additional information, including other authors, author contributions ...
LAST 30 PRESS RELEASES:
[Press-News.org] Moffitt research finds non-small cell lung cancer drug lorlatinib targets additional protein
Lorlatinib co-targets PYK2 and forms a multiprotein complex with SRC suggesting combo therapy could be more beneficial for patients
